Bayer AG | Cash Flow

Fiscal year is January-December. All values EUR Millions.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
3,186
3,343
4,013
3,756
3,248
1,711
Depreciation, Depletion & Amortization
2,611
2,695
3,102
2,351
2,141
2,999
Other Funds
7
3
22
58
154
104
Funds from Operations
5,619
6,565
7,056
8,707
7,341
2,882
Changes in Working Capital
661
1,010
712
323
229
4,363
Net Operating Cash Flow
4,958
5,555
6,344
8,384
7,570
7,245
Capital Expenditures
2,157
2,371
2,517
2,578
2,366
Sale of Fixed Assets & Businesses
232
447
195
113
241
Purchase/Sale of Investments
301
177
370
6,335
1,230
Net Investing Cash Flow
2,706
15,646
2,868
8,818
600
Cash Dividends Paid - Total
1,571
1,737
1,861
2,068
2,233
Issuance/Reduction of Debt, Net
619
-
-
-
-
Net Financing Cash Flow
2,197
10,098
3,322
444
1,149
Net Change in Cash
36
191
1
37
5,682
Free Cash Flow
2,801
3,184
3,827
5,806
5,204
Deferred Taxes & Investment Tax Credit
-
-
1,031
572
202
1,932
Net Assets from Acquisitions
1,082
13,545
176
-
158
Other Sources
-
-
-
-
453
Change in Capital Stock
-
-
1,490
3,300
3,717
Exchange Rate Effect
91
184
153
27
139
Other Uses
-
-
-
18
-

About Bayer

View Profile
Address
Kaiser-Wilhelm-Allee 1
Leverkusen Nordrhein-Westfalen 51368
Germany
Employees -
Website http://www.bayer.com
Updated 07/08/2019
Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment engages in the development, production and marketing of prescription products for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology and ophthalmology; diagnostic imaging equipment and the necessary contrast agents.